Univest
Univest
  • Markets

Biopol Chemicals IPO Listing at 3.00% Premium at ₹111.00 Per Share 

  • February 13, 2026
  • Posted by: Neeraj Pandey
  • Category: IPO
No Comments
Biopol Chemicals IPO Listing

Biopol Chemicals IPO Listing Today: The Biopol Chemicals IPO was subscribed 22.33 times at the time of its closing. In this subscription, qualified institutional buyers (QIBs) received 21.05 times, and non-institutional investors (NIIs) received 24.49 times. The retail quota of the issue was subscribed to 33.25%. Before delving deeper into the topic, go through the details of the Biopol Chemicals IPO.

Table of Contents

Toggle
  • Biopol Chemicals IPO
  • Biopol Chemicals Listing
  • About the Biopol Chemicals IPO
  • Biopol Chemicals Limited Financials
    • Explanation
  • Recent Articles

Biopol Chemicals IPO

It is a book-building issue IPO of ₹31.26 crore, comprising an entirely fresh issue of 0.29 crore shares. The issue will be listed on NSE and SME on its tentative listing date, 13th February 2026. The Biopol Chemicals IPO date is scheduled from 6th January 2026 to 10th January 2026. The face value of Biopol Chemicals shares stands at ₹10 per share, and the IPO Issue price band is set at ₹102 to ₹108 per share

IPO Allotment Date11th February 2026
IPO Open Date6th January 2026
IPO Close Date10th February 2026
Refund Initiation 12th February 2026
Issue Size28,94,400 shares(agg. up to ₹31 Cr)
Face Value₹10 per share
Lot Size1,200 Shares
Issue Price ₹102 to ₹108 per share
Issue TypeBookbuilding IPO
Listing AtNSE SME
Listing Date13th February 2026

Biopol Chemicals Listing

On the NSE & SME platforms, Biopol Chemicals shares are listed at ₹111.00 per share, reflecting a 3.00% premium over the issue price of ₹108 per share. 

About the Biopol Chemicals IPO

Biopol Chemicals Limited was incorporated in the year 2023. The company is engaged in the manufacture and trading of speciality chemicals comprising silicones, emulsifiers, biochemicals, and polyelectrolytes. The company’s portfolio of products comprises 66 products, comprising 40 silicone-based products, 5 emulsifier-based products, 15 biochemical-based products, and 6 polyelectrolyte-based products. The products find their applications in the textile, home care, agriculture, and industrial chemicals industries. The company follows a B2B business model wherein the company sells its products to institutional clients and not directly to retail end-consumers. The company operates the 4 establishments located in West Bengal and Gujarat, comprising their manufacturing unit, warehouse, and corporate office in West Bengal, and the registered office located in West Bengal.

Biopol Chemicals Limited Financials

The company’s financial analysis is essential before applying for the Biopol Chemicals IPO. See the table for Biopol Chemicals Limited’s financials. 

Year Ended31st Dec 2025 (in cr.)31st March 2025 (in cr.)31st March 2024 (in cr.)
Assets48.8831.4817.56
Revenue48.9749.1517.43
Profit After Tax6.004.332.96
EBITDA8.996.534.43
Net Worth19.5413.539.20
Reserves and Surplus11.635.621.29
Total Borrowings14.927.693.58

Explanation

Biopol Chemicals Limited’s revenue increased by 181.98% from ₹17.43 crores in March 2024 to ₹49.15 crores in March 2025. Moreover, the company’s PAT increased by 46.28% from ₹2.96 crores in March 2024 to ₹4.33 crores in March 2025.

Recent Articles

Best 1-Year SIP Plans 2026: Top Monthly SIP Plans in India

Fractal Industries IPO Review 2026: GMP Rises Rises 2.31%, Key Investor Insights

Marushika Technology IPO Day 1: Subscription at 0.08x, GMP Flat | Live Updates

PAN HR Solutions IPO Listing Preview: What to Expect Now?

Biopol Chemicals IPO Listing Preview: What to Expect Now?

Aye Finance IPO Listing Preview: What to Expect Now?

Fractal Analytics IPO Listing Preview: What to Expect Now?



IPO IPO Listing
Author: Neeraj Pandey
Neeraj Pandey is a Financial Content Writer at Univest, covering Indian equity markets with a specialisation in quarterly earnings previews and analyst consensus analysis. His published work tracks Q4 FY26 results across 10+ sectors — from IT heavyweights like Infosys and TCS to PSUs like Coal India and Balmer Lawrie, and mid-caps like Neuland Laboratories, MCX, and Whirlpool of India. His writing approach is data-first: every article anchors on NSE/BSE filings, analyst consensus estimates (revenue, PAT, EBITDA margins), 52-week price context, and YoY/QoQ comparisons — giving retail investors the same structured framework institutional desks use before an earnings event. He combines SEO-optimised structure with rigorous data sourcing, ensuring each preview ranks for investor search intent while meeting SEBI editorial standards. All articles are reviewed by Univest's in-house equity research team, led by Ankit Jaiswal, Senior Equity Research Analyst, to meet SEBI editorial standards.

Leave a Reply Cancel reply